Clinical trials
alpha 1-Antitrypsin Deficiency trials in Sweden
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 4 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Grifols Therapeutics LLC | 4 |
| CSL Behring | 2 |
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2 |
| Kamada, Ltd. | 2 |
| Sanofi | 2 |
| Takeda | 2 |
| AIRNA Corporation | 1 |
| Arrowhead Pharmaceuticals | 1 |
| Mereo BioPharma | 1 |
| Vertex Pharmaceuticals Incorporated | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| alpha 1-Antitrypsin Deficiency | 18 |
| Emphysema | 8 |
| Lung Diseases | 3 |
| Pulmonary Emphysema | 3 |
| Genetic Diseases, Inborn | 2 |
| Pathologic Processes | 2 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Respiratory Tract Diseases | 2 |
| Subcutaneous Emphysema | 2 |
| Congenital Abnormalities | 1 |
Trials
Showing 76 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.